My Account

Risk Management
Workers Comp & Safety
Employee Benefits
International
People
Events
BI Intelligence
Magazine
- Current Issue
- Past Issues
DEI Institute

Recent Quotes

View Full List

My Watchlist

Indicators

Business Insurance Index

Markets:

Overview

News

Currencies

International

Treasuries

Novartis AG Common Stock (NY:NVS)

161.43 +1.37 (+0.86%)

Streaming Delayed Price Updated: 12:31 PM EST, Feb 12, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Novartis AG Common Stock

< Previous 1 2

...

6 7 8 9 10 11 12 13 14

...

55 56 Next >

Novartis’ Blockbuster Drug Fails Late-Stage Trial In Disease Causing Blood Vessel Inflammation, But Retail Turns Bullish ↗

July 03, 2025

Giant cell arteritis (GCA) is the most common form of systemic vasculitis, a group of rare autoimmune diseases characterized by inflammation of blood vessels.

Via Stocktwits

Novartis' Cosentyx Fails Late-Stage Giant Cell Arteritis Trial ↗

July 03, 2025

Cosentyx missed its main goal in a Phase 3 GCA study, but showed lower steroid use. Novartis plans full review of the trial data.

Via Benzinga

Is Pfizer Stock a Yield Trap? ↗

July 03, 2025

Via The Motley Fool

Topics Intellectual Property

FDA Flags Weight Loss Risk In ADHD Meds For Kids — J&J, Novartis Escape New Warning ↗

June 30, 2025

The updated label applies to extended-release stimulants prescribed off-label to children under six, following data showing higher drug exposure and side effect rates in that age group.

Via Stocktwits

FDA Eases Access To Life-Saving Gene Therapies For Blood Cancers ↗

June 30, 2025

FDA lifts REMS for approved CAR-T therapies, easing hospital restrictions and signaling broader future access in oncology and autoimmune treatment.

Via Benzinga

Is Novartis Gaining or Losing Market Support? ↗

June 04, 2025

Via Benzinga

Could This Be the Best High-Dividend ETF to Buy Right Now? ↗

June 30, 2025

Via The Motley Fool

Topics ETFs Economy

Incyte CEO Shake-Up Sparks M&A Buzz As RBC Analyst Highlights Meury’s Track Record: Retail Is All In ↗

June 27, 2025

Bill Meury previously led Karuna Therapeutics through a $14 billion sale to Bristol Myers Squibb and steered Anthos Therapeutics ahead of its acquisition by Novartis.

Via Stocktwits

Topics Intellectual Property

5 Biotech Stocks with Highly Anticipated Pending Results ↗

June 26, 2025

Via Stocktwits

Topics Intellectual Property

Why New Incyte CEO Bill Meury Is Stoking Investors' M&A Hopes ↗

June 26, 2025

Bill Meury will take the place of Herve Hoppenot, who is retiring after 11 years at Incyte's helm.

Via Investor's Business Daily

Biogen-Ionis Partnered Drug Shows Benefit In Children With Spinal Muscular Atrophy Previously Treated With Novartis' Zolgensma ↗

June 25, 2025

Biogen's early-stage spinal muscular atrophy drug salanersen showed safety, motor improvements and 70% reduction in neurodegeneration markers after one-year dosing.

Via Benzinga

Can Biogen Outdo Its Own Spinal Muscular Atrophy Drug? ↗

June 25, 2025

Biogen is hoping to top its own spinal muscular atrophy treatment, Spinraza, with a next-generation version.

Via Investor's Business Daily

Shuttle Pharma Ramps Up Fight Against Glioblastoma With New Leadership, Promising Clinical Trial, and Bold Innovations ↗

June 23, 2025

Via Stocktwits

Topics Cannabis

Analyst Flags Septerna As Undervalued Biotech Play With Significant Upside ↗

June 23, 2025

Septerna gains Buy rating as HC Wainwright highlights undervaluation, strong pipeline, and key partnership with Novo Nordisk in metabolic diseases.

Via Benzinga

NOVARTIS AG-SPONSORED ADR (NYSE:NVS) – A Solid Value Pick in Pharmaceuticals ↗

June 23, 2025

NOVARTIS AG (NYSE:NVS) offers strong profitability, solid financial health, and an attractive valuation, making it a potential value pick in the pharmaceuticals sector.

Via Chartmill

Novo Nordisk Moves Amycretin Into Phase 3 Trials For Weight Management, Becomes Europe's Largest Company ↗

June 13, 2025

Novo Nordisk will begin phase 3 trials for amycretin in early 2026 following promising weight loss data and regulatory discussions.

Via Benzinga

Novartis' Fabhalta Delivers Hemoglobin Gains, Reduces Fatigue In Patients With Rare Blood Disorder ↗

June 12, 2025

Novartis' Fabhalta improved hemoglobin, reduced fatigue and eliminated transfusion need in a Phase 3B PNH study presented at the 2025 EHA Congress.

Via Benzinga

PU Prime Broadens Portfolio with New Global Indices

June 11, 2025

Via GlobePRwire

Topics Derivatives Economy

Global Billion Dollar Oncology Industry Experiencing Substantial Growth Driven by Increasing Cancer Incidences

June 11, 2025

EQNX::TICKER_START (NNASDAQ:ONCY),(TSX:ONC),(NYSE:NVS),(NASDAQ:BNTX),(NASDAQ:ARVN),(NYSE:PFE),(NYSE:BMY) EQNX::TICKER_END

Via FinancialNewsMedia

Topics Artificial Intelligence

2 Dividend Growth Stocks to Buy and Hold Forever ↗

June 06, 2025

Via The Motley Fool

Topics Intellectual Property

Rapt Therapeutics Get A Bullish Recommendation On ‘Significant Opportunity’ For Allergy Drug Candidate: Retail Worries About Cash Position ↗

June 05, 2025

Clear Street’s initiated with a $3 price target, highlighting RPT904b as a “potentially best-in-class anti-IgE antibody.”

Via Stocktwits

Topics ETFs

Global Billion Dollar Oncology Industry Experiencing Substantial Growth Driven by Increasing Cancer Incidences

June 11, 2025

From FN Media Group LLC

Via GlobeNewswire

Alcon Secures First FDA Approval Since Novartis Spin-Off In 2019 ↗

May 29, 2025

FDA approves Alcon's Tryptyr for dry eye disease, backed by Phase 3 trials showing strong efficacy in increasing natural tear production.

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

May 28, 2025

Via Benzinga

The Smartest Vanguard ETF to Buy With $500 Right Now ↗

May 21, 2025

Via The Motley Fool

Topics ETFs

Prediction: This "Magnificent Seven" Stock Will Be the Most Valuable Company in the World in 10 Years ↗

May 16, 2025

This company stands to benefit from the advances in artificial intelligence more than any other business.

Via The Motley Fool

Topics Artificial Intelligence

Lazard Transforms Mutual Fund Into IEQ ETF Amid Rising Demand For International Stocks ↗

May 15, 2025

IEQ inherits the portfolio DNA of its mutual fund ancestor, now in the tax-efficient wrapper increasingly favored by investors.

Via Benzinga

Topics ETFs

Sanofi To Navigate Tariff Impact With $20 Billion In Spending Through 2030 ↗

May 14, 2025

Sanofi plans $20 billion US investment by 2030 to expand R&D and manufacturing, aiming to boost medicine production and job creation across states.

Via Benzinga

Here's My Favorite High-Dividend ETF to Buy Right Now ↗

May 14, 2025

Via The Motley Fool

Topics ETFs

Trump’s ‘Most Favored Nation’ Drug Plan Likely To Face Pushback, JP Morgan Analysts Say ↗

May 12, 2025

JPMorgan analysts said President Trump’s "most favored nation" drug pricing order is unlikely to move forward without Congressional support and will likely face legal and industry resistance, limiting...

Via Stocktwits

Topics ETFs Government Stocks

< Previous 1 2

...

6 7 8 9 10 11 12 13 14

...

55 56 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.

Information

About Us
Contact
Advertise
Privacy Policy
Terms & Condition